Abstract:The cell surface metalloprotease ADAM17 (a disintegrin and metalloprotease 17) and its binding partners iRhom2 and iRhom1 (inactive Rhomboid-like proteins 1 and 2) modulate cell–cell interactions by mediating the release of membrane proteins such as TNFα (Tumor necrosis factor α) and EGFR (Epidermal growth factor receptor) ligands from the cell surface. Most cell types express both iRhoms, though myeloid cells exclusively express iRhom2, and iRhom1 is the main iRhom in the mouse brain. Here, we report that iRhom2 is uniquely expressed in olfactory sensory neurons (OSNs), highly specialized cells expressing one olfactory receptor (OR) from a repertoire of more than a thousand OR genes in mice. iRhom2-/- mice had no evident morphological defects in the olfactory epithelium (OE), yet RNAseq analysis revealed differential expression of a small subset of ORs. Notably, while the majority of ORs remain unaffected in iRhom2-/- OE, OSNs expressing ORs that are enriched in iRhom2-/- OE showed fewer gene expression changes upon odor environmental changes than the majority of OSNs. Moreover, we discovered an inverse correlation between the expression of iRhom2 compared to OSN activity genes and that odor exposure negatively regulates iRhom2 expression. Given that ORs are specialized G-protein coupled receptors (GPCRs) and many GPCRs activate iRhom2/ADAM17, we investigated if ORs could activate iRhom2/ADAM17. Activation of an olfactory receptor that is ectopically expressed in keratinocytes (OR2AT4) by its agonist Sandalore leads to ERK1/2 phosphorylation, likely via an iRhom2/ADAM17-dependent pathway. Taken together, these findings point to a mechanism by which odor stimulation of OSNs activates iRhom2/ADAM17 catalytic activity, resulting in downstream transcriptional changes to the OR repertoire and activity genes, and driving a negative feedback loop to downregulate iRhom2 expression.

Structural Insights into the Activation and Inhibition of the ADAM17-iRhom2 Complex

Substrate-selective Protein Ectodomain Shedding by ADAM17 and Irhom2 Depends on Their Juxtamembrane and Transmembrane Domains.

Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis

Structures of an Eph receptor tyrosine kinase and its potential activation mechanism.

Pathological mutations reveal the key role of the cytosolic iRhom2 N-terminus for phosphorylation-independent 14-3-3 interaction and ADAM17 binding, stability, and activity

The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth

Analysis of the function of ADAM17 in iRhom2-curly-bare (cub) and Tylosis with Oesophageal Cancer (TOC) mutant mice.

Analysis of the function of ADAM17 in iRhom2 curly-bare and tylosis with esophageal cancer mutant mice

Molecular Switch In Human Diseases-Disintegrin And Metalloproteinases, Adam17

Catalytic Properties of ADAM19

Conformational Transitions and Activation of the Adhesion Receptor CD97.

Structural Characterization of the Ectodomain of a Disintegrin and Metalloproteinase-22 (ADAM22), a Neural Adhesion Receptor Instead of Metalloproteinase: Insights on ADAM Function.

The Protease ADAM17 at the Crossroads of Disease: Revisiting its Significance in Inflammation, Cancer, and Beyond

iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells

Implications for Odorant Receptor Regulation and Activity-Dependent Adaptation

TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.

iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE

Immunomodulatory role of metalloproteinase ADAM17 in tumor development

Cryo-EM structures of PI3K reveal conformational changes during inhibition and activation

An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth

Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 on cancer cells